新型生物制剂治疗类风湿关节炎的疗效与耐受性：当前最佳证据
The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
作者信息
Siddiqui M Asif A
机构信息
Wolters Kluwer Health /Adis, Auckland, New Zealand.
出版信息
Curr Opin Rheumatol. 2007 May;19(3):308-13. doi: 10.1097/01.bor.0000265447.48722.04.
Abstract
(1) Biologics have had a tremendous impact on the management of rheumatoid arthritis.(2) Three new biologics have been approved or filed for approval for the treatment of rheumatoid arthritis in the last 2 years: abatacept, rituximab, and tocilizumab.(3) The utility of the newer biologics against the background of existing, well established biologics (infliximab, etanercept, adalimumab, and anakinra) has not been evaluated systematically.
摘要
（1）生物制剂对类风湿关节炎的治疗产生了巨大影响。（2）在过去两年中，已有三种新型生物制剂被批准或申请批准用于治疗类风湿关节炎：阿巴西普、利妥昔单抗和托珠单抗。（3）在已有的成熟生物制剂（英夫利昔单抗、依那西普、阿达木单抗和阿那白滞素）背景下，新型生物制剂的效用尚未得到系统评估。
Zotero 插件